NMN and NR both raise blood NAD+ by about twofold, and in the only head-to-head human trial they did it equally well, yet neither has beaten placebo on most clinical outcomes, so the honest verdict is that they are near-identical NAD+ boosters, and your choice should come down to price, dose, and legal status.
What NMN and NR actually are
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both vitamin B3 derivatives that your body uses as raw material to build NAD+, a coenzyme every cell needs for energy production and DNA repair. NAD+ levels fall with age, which is why both compounds are sold as longevity supplements. The structural difference is small but real: NMN carries a phosphate group that NR lacks, which puts NMN one step closer to NAD+ in the biosynthesis pathway. Inside the cell, NR is converted back to NMN by the enzyme NRK1, which is rate-limiting for both compounds, so the two molecules converge on the same pathway before becoming NAD+.
That convergence matters because most marketing treats them as rivals with different mechanisms. In practice, they are two doors into the same room. The question is not which molecule is fundamentally better, it is which one has better human evidence, a better price, and a cleaner safety record at the dose you would actually take.
The head-to-head trial: a tie on the only direct test
Until recently, every NMN versus NR article rested on indirect comparison, matching one trial of NMN against a different trial of NR. That changed with the first direct comparison, published in Nature Metabolism by Christen and colleagues from Nestle Health Science. The trial gave 65 healthy adults an average age of 34.7 years either NR, NMN, nicotinamide, or placebo daily for 14 days. Doses were 1 gram of NR, 1 gram of NMN, and 0.5 grams of nicotinamide.
After 14 days, NR and NMN both raised circulating NAD+ by about twofold, while nicotinamide had no significant effect on baseline levels despite a brief acute rise. The result was a clean tie on the one outcome the trial measured. The trial also produced a surprise about mechanism: the researchers found that gut bacteria convert both NR and NMN into nicotinic acid, which then raises NAD+ through the Preiss-Handler pathway. Neither precursor appeared to raise blood NAD+ by acting on blood cells directly. That finding leaves open whether intact NMN reaches the bloodstream at all, a question the trial did not settle.
Two caveats belong here. The trial ran 14 days, which is long enough to move a blood marker and far too short for any functional endpoint like energy, cognition, or aging. And the trial was open-label rather than double-blind, though it was placebo-controlled and randomized. It is registered as NCT05517122.
What the wider human evidence shows
Outside the head-to-head trial, each compound has its own body of human research, and the pattern is strikingly similar: both reliably raise blood NAD+, and both struggle to show that the rise translates into measurable health gains.
NR: the longer human record
NR has more published human trials than NMN, including longer-term safety data. The foundational study is Trammell and colleagues (2016), which gave healthy adults single doses of 100, 300, and 1,000 mg of NR and found dose-dependent increases in blood NAD+, up to 2.7-fold at the 1,000 mg dose. That study established that oral NR is bioavailable in humans. Martens and colleagues (2018) ran a 2 by 6-week crossover trial in healthy middle-aged and older adults and again found that NR raised NAD+, with good tolerability. At the high end of dosing, a trial in Parkinson’s disease patients used 3,000 mg per day (1,500 mg twice daily) for four weeks, raised NAD+ up to fivefold, and reported a clean safety profile.
NMN: the faster-growing record
NMN research has accelerated sharply since 2022, and a 2025 meta-analysis pooled 12 randomized controlled trials with 513 adults. The meta-analysis confirmed that NMN raises blood NAD+ overall, but it found no significant difference from placebo on most of the other outcomes it pooled. That gap between a moving biomarker and unmoved clinical outcomes is the central fact about both compounds. A separate 2025 meta-analysis of 12 trials reached the same conclusion for the pair: most clinically relevant outcomes showed no significant difference from placebo for either compound.
Individual NMN trials do show scattered positive signals. Igarashi and colleagues (2022) gave healthy older men 250 mg of NMN per day for 6 or 12 weeks and found raised blood NAD+. Morifuji and colleagues (2024) gave 60 older adults 250 mg per day for 12 weeks and found raised blood NAD+ plus shorter 4-meter walking times and better sleep-quality scores than placebo, though the main stepping test showed no difference. Liao and colleagues (2021) gave 48 recreational runners 600 or 1,200 mg per day for 6 weeks and found improved measures of aerobic capacity versus placebo while they trained. A multicenter trial cited in the 2025 literature found 600 mg per day to be the apparent sweet spot for physical performance. Each of these is a small, short trial, and the 2025 meta-analysis rated risk of bias as “some concerns” in seven of its 12 studies and high in the other five.
NMN vs NR comparison table
| Factor | NMN | NR | Verdict |
|---|---|---|---|
| Blood NAD+ rise | About 2x in 14 days at 1 g/day (Christen, Nature Metabolism) | About 2x in 14 days at 1 g/day (same trial) | Tie |
| Human trial count | 12 RCTs in 2025 meta-analysis (513 adults) | More published trials, including longer-term safety data | NR ahead on volume |
| Best-studied dose | 250 to 600 mg/day (Igarashi 2022; Morifuji 2024; Liao 2021) | 250 to 1,000 mg/day (Trammell 2016; Martens 2018) | Comparable |
| Clinical outcomes vs placebo | No significant difference on most pooled outcomes (Zhang 2025 meta-analysis) | Same pattern in the 2025 meta-analysis of 12 RCTs | Tie, and not a good one |
| Physical performance signal | 600 mg/day improved aerobic capacity in runners (Liao 2021) | No comparable performance signal in trials to date | NMN, weakly |
| Safety data | Trials up to 12 weeks; long-term data limited | Trials up to 3,000 mg/day for 4 weeks; longer record | NR slightly ahead |
| US legal status | Lawful supplement again since FDA reversal, Sept 2025 | Lawful supplement; GRAS-notified ingredient | Both lawful |
| EU status | Not authorized as a food supplement | Capped at 300 mg/day | NR |
| Typical price per gram | About $4.07 (single market survey) | About $3.67 (single market survey) | NR, slightly cheaper |
Doses used in human trials
Dose is where the two compounds differ most in practice, because the trial record clusters at different points. For NMN, the most common trial doses are 250 mg per day (Igarashi 2022; Morifuji 2024) and 600 mg per day (Liao 2021), with 1,200 mg per day also tested in runners. The 600 mg dose is the one with the best performance signal, and it is the dose the multicenter data points to as optimal for physical performance. For NR, the most common trial doses are 250 to 1,000 mg per day, with the 1,000 mg single dose producing the largest measured NAD+ rise in Trammell 2016 and 1,000 mg per day used in the 10-week mild cognitive impairment trial, where NAD+ rose 2.6-fold with no cognitive change.
Neither compound has a dose-response curve for clinical outcomes, only for the NAD+ biomarker. Taking more raises blood NAD+ further, but no trial has shown that a higher NAD+ number buys better health. That is the single most important fact for anyone choosing a dose: you are optimizing a lab value, not a proven outcome.
Price and value
On price, NR holds a small edge. A market survey of listed products found median prices of about $4.07 per gram for NMN and about $3.67 per gram for NR, making NR roughly 10 percent cheaper per gram. That survey is a single source and was not verified across retailers at the time of writing, so treat it as a snapshot rather than a settled fact. At typical trial doses, the monthly cost difference is a few dollars either way, which means price should not drive the decision unless you plan to take the compounds for years. If you do, the 10 percent gap compounds.
Legal status: NMN is lawful again in the US
NMN spent three years in regulatory limbo. In late 2022, the FDA told industry that NMN did not qualify as a dietary supplement because it had been authorized for investigation as a drug before being marketed as a supplement, and retailers including Amazon pulled NMN products. After a Natural Products Association challenge, the FDA reversed course: in letters dated September 29, 2025, it concluded NMN is not excluded from the dietary-supplement definition, and on December 2, 2025, it issued reinstatement letters confirming NMN’s status as a lawful new dietary ingredient. As of 2026, NMN is again sold openly as a dietary supplement in the United States. The reversal says nothing about whether NMN is safe or works; it is a legal reading, not an approval.
In the European Union, the picture is different: NMN is not authorized as a food supplement, and NR is capped at 300 mg per day. Anyone buying from outside the United States should check local rules before ordering.
What Reddit users report
Online reports from Reddit and longevity forums are consistent with the trial data in one respect and misleading in another. Users commonly report better sleep, more stable energy, and faster workout recovery on both compounds, with NMN users slightly more likely to mention sleep and NR users slightly more likely to mention nothing at all. These are reports, not results: no one in a forum thread is blinded, and the placebo effect on subjective energy is large. The honest way to read them is that both compounds feel subjectively fine to most people who take them, which matches the trials’ clean tolerability record, and that no consistent difference between the two emerges from user experience.
Who should skip this
Skip both compounds if you are pregnant or breastfeeding, because neither has safety data in pregnancy. Skip them if you are under 18, for the same reason. People with active cancer should talk to an oncologist first, because NAD+ biology intersects with cell growth pathways and the evidence cuts both ways in preclinical work. People taking medications with narrow therapeutic windows should check with a clinician, since NAD+ precursors are not inert. And anyone expecting a longevity intervention should know the truth: no human trial has shown that either compound extends lifespan or healthspan. The evidence supports a blood marker going up, not a life getting longer.
If you have a limited supplement budget, the money is better spent on interventions with proven outcome data, such as exercise, sleep, and blood pressure control. Our evidence review of NMN and NAD+ covers the broader longevity case in more detail, and our metformin longevity debate covers a compound with a much larger human evidence base.
The verdict
NMN vs NR is a tie on the only outcome ever tested head to head, and a tie on the disappointing follow-up: neither one has shown clinical benefits beyond raising a blood marker. NR has the longer safety record, the slightly lower price, and lawful status in the EU. NMN has the better performance signal at 600 mg per day and a faster-growing trial base. If you are going to take one, NR is the marginally safer default, NMN is the marginally more interesting bet for athletic performance, and neither is worth choosing over the basics. If you want a clinician-guided approach to longevity interventions, our guide to the best longevity clinics in Los Angeles lays out what a workup actually involves.
FAQ
Is NMN better than NR?
On the only direct evidence, no. The Christen head-to-head trial found both raised blood NAD+ by about twofold over 14 days, and meta-analyses found neither beat placebo on most clinical outcomes. NR has a longer safety record and a slightly lower price; NMN has a better performance signal at 600 mg per day.
What is the best dose of NMN?
The best-studied doses are 250 mg per day and 600 mg per day. The 250 mg dose raised blood NAD+ in older adults over 12 weeks (Morifuji 2024), and the 600 mg dose improved aerobic capacity in runners over 6 weeks (Liao 2021). No dose has proven clinical benefits beyond the NAD+ biomarker.
What is the best dose of NR?
The best-studied doses are 250 to 1,000 mg per day. A single 1,000 mg dose raised blood NAD+ up to 2.7-fold (Trammell 2016), and 1,000 mg per day for 10 weeks raised NAD+ 2.6-fold in older adults with mild cognitive impairment, with no cognitive change.
Is NMN legal in the US now?
Yes. The FDA reversed its 2022 exclusion in letters dated September 29, 2025, and issued reinstatement letters on December 2, 2025, confirming NMN is a lawful dietary supplement ingredient. It is not authorized in the EU, and NR is capped at 300 mg per day there.
Can you take NMN and NR together?
There is no human trial testing the combination, and no reason to expect synergy, since both feed the same NAD+ pathway through the same rate-limiting enzyme. Taking both is paying twice for one mechanism.
Does NMN or NR actually slow aging?
No human trial has shown either compound slows aging, extends lifespan, or improves healthspan. Both raise blood NAD+, and that is where the proven effect ends. The rest is extrapolation from animal studies, which have repeatedly failed to translate.